Dilution of Share Value Through Exercise of Stock Options
First written in FY2016. 7 of 10 entries say "Worsened", first in FY2018-Q2. Latest entry: FY2025.
Crooz moved to the "Worse" side of this theme in 2017, 3 years before the typical company in this theme (2020).
The whole theme swung hardest in 2017: 37 of 68 companies on the "Worse" side.
30 other companies' latest entry also says "Worsened".
- FY2025WorsenedAnnual report
「Five types of stock acquisition rights (46,535 rights, representing 4,653,500 common shares).」
The company disclosed total underlying shares of 4,653,500 for the five types of stock acquisition rights outstanding at the end of the fiscal year. Although 3,000 rights under Series 13 expired, the potential shares subject to dilution remain substantial. - FY2024-Q2WorsenedAnnual report
「(2) Recipients and number of recipients allocated stock acquisition rights, and number of stock acquisition rights 4 directors 25,880 rights (3) Class and number of shares underlying stock acquisition rights Common shares 2,588,000 shares (9) Exercise period of stock acquisition rights 28 October 2023 to 27 October 2033」
Four directors were issued 25,880 stock acquisition rights, representing 2,588,000 underlying shares. The exercise period is from 28 October 2023 to 27 October 2033, expanding the potential shares subject to dilution. - FY2021RestatedAnnual report
「During the consolidated fiscal year, stock acquisition rights for 14,000 common shares were exercised.」
The issuance of shares through the exercise of stock acquisition rights was confirmed as a fiscal-year result, reconfirming the potential dilution issue. - FY2021-Q2WorsenedAnnual report
「1 July 2020–30 September 2020 (Note) 14,000 12,957,600 3,653 460,163 3,653 450,163 (Note) Increase resulting from the exercise of stock acquisition rights.」
The number of shares outstanding increased by 14,000 shares during the quarter through the exercise of stock acquisition rights, confirming actual dilution. - FY2020WorsenedAnnual report
「1 company officer 20,000 rights Class and number of shares underlying stock acquisition rights Common shares 2,000,000 shares」
After the filing date, 20,000 Series 16 stock acquisition rights were issued, representing 2 million underlying shares, expanding the potential shares subject to dilution. - FY2019-Q1WorsenedAnnual report
「Increase resulting from the exercise of stock acquisition rights.」
From 1 April 2018 to 30 June 2018, the number of shares outstanding increased by 5,000 shares through the exercise of stock acquisition rights. - FY2018WorsenedAnnual report
「During the consolidated fiscal year, stock acquisition rights for 14,500 common shares were exercised.」
In addition to the issuance of 14,500 shares through the exercise of stock acquisition rights, the filing describes an issuance of Series 15 stock acquisition rights with 387,700 underlying shares, expanding the potential shares subject to dilution. - FY2018-Q2WorsenedAnnual report
「Number of stock acquisition rights (rights) 790 rights (Note 1) Number of shares underlying stock acquisition rights (shares) 79,000 (Note 1)」
During the second quarter accounting period, 790 stock acquisition rights were issued, representing 79,000 underlying shares. The potential shares subject to dilution upon exercise are specified, but there is no description of dilution having occurred through exercise as of the end of the quarter. - FY2017RestatedAnnual report
「Our group may continue to grant stock options as incentives to secure talented directors and employees. If these stock options are exercised, they could dilute the value of the shares held.」
Reconfirms the possibility of granting stock options in the future to secure personnel and the dilution risk upon exercise. - FY2016First statedAnnual report
「Our group grants stock options to improve the motivation of directors and employees. If these stock options are exercised, they could dilute the value of the shares held.」
Describes the potential dilution associated with stock options used to secure personnel and improve motivation.